trending Market Intelligence /marketintelligence/en/news-insights/trending/YiS4GvcI9kZsodlZAf3aRg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Dova Pharmaceuticals files for $74.8M IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Dova Pharmaceuticals files for $74.8M IPO

Dova Pharmaceuticals Inc. filed for an IPO of up to $74.8 million of its common stock.

The company plans to apply for listing of its common stock on the Nasdaq Global Market under the symbol DOVA.

Dova plans to use the net proceeds from the offering to fund the commercialization of avatrombopag, a drug to treat low blood platelet count, if approved; to fund clinical trials of the drug for additional indications beyond its initial indication; as repayment to Eisai Co. Ltd. of a portion of obligations under the Eisai note; and the balance for other general corporate purposes, including general and administrative expenses and working capital.

The underwriters for the IPO include J.P. Morgan Securities LLC, Jefferies LLC and Leerink Partners LLC.

Dova is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count.